Recently, Torkinib, a selective mTOR inhibitor, has been demonstrated to reverse the pathological changes of stress granules in induced pluripotent stem cell (iPSC)-derived neurons with P525L FUS mutation, which is one of the most severe mutations of ALS [101]. This evidence concerns the gene MTOR and amyotrophic lateral sclerosis.